- Home
- CMP vs COLL Comparison
CMP vs COLL Comparison
Compare CMP & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMP | COLL |
|---|---|---|
| Founded | 1993 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CMP | COLL |
|---|---|---|
| Price | $25.63 | $23.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $21.50 | ★ $51.40 |
| AVG Volume (30 Days) | 374.9K | ★ 842.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | $43.71 | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $16.40 | $23.11 |
| 52 Week High | $34.50 | $50.79 |
Technical Indicators
Market Signals| Indicator | CMP | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 23.91 |
| Support Level | $24.49 | N/A |
| Resistance Level | $25.80 | $35.89 |
| Average True Range (ATR) | 0.89 | 1.03 |
| MACD | 0.25 | -0.09 |
| Stochastic Oscillator | 72.32 | 4.55 |
Price Performance
Historical ComparisonAbout CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.